About: The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report
Creator	Berlot, Giorgio Amato, Paola Bianco, Francesco Chiella, Fabrizio Gerini, Ugo Piva, Marco Randino, Anna Roman Pognuz, Erik Tomasini, Ariella Tomietto, Paola Trenti, Tommaso Di Maso, Vittorio Fata, Cristina
source	Medline; PMC
abstract	The SARS-COV-2-19-associated respiratory involvement is caused by the massive release of inflammatory cytokines ultimately leading to interstitial pneumonia and acute respiratory distress syndrome (ARDS). In the absence of an effective antiviral treatment, a reasonable causal approach could be constituted by the neutralization of these substances. The authors describe the clinical course of a patient with SARS-COV-2-19 interstitial pneumonia treated with the combination of an anti-interleukin 6 (IL-6) agent (tocilizumab) and hemoadsorption (HA). This combination was used to abate the surge of inflammatory mediators leading to the lung damage. Blood levels of IL-6 and C-reactive protein (CRP) were measured before the initiation of the treatment and in the following 3 days. At the end of the treatment, the values of IL-6 and CRP decreased from 1,040 to 415 pg/mL and from 229 to 59 mg/L, respectively. The gas exchanges and the chest imaging rapidly improved, and the patient was extubated 10 days later. The combination of tocilizumab and HA could be valuable in the treatment of SARS-COV-2-19-associated pneumonia and ARDS that are caused by the release of inflammatory mediators.
has issue date	2020-07-21(xsd:dateTime)
bibo:doi	10.1159/000509738
bibo:pmid	32694244
has license	no-cc
sha1sum (hex)	0eb926f409d2bfd123718cd23812e4bccc622b3e
schema:url	https://doi.org/10.1159/000509738
resource representing a document's title	The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report
has PubMed Central identifier	PMC7445375
has PubMed identifier	32694244
schema:publication	Nephron Clin Pract
resource representing a document's body	covid:0eb926f409d2bfd123718cd23812e4bccc622b3e#body_text
is schema:about of	named entity 'SARS-COV-2' named entity 'antiviral treatment' named entity 'neutralization' named entity 'SARS-COV-2' named entity 'authors' named entity 'Tocilizumab' named entity 'RAPIDLY' named entity 'LUNG' named entity 'TREATMENT' named entity 'COMBINATION' named entity 'IMPROVED' named entity 'PROTEIN ' named entity 'DAYS' named entity '2-19' named entity 'PATIENT' named entity 'USED' named entity 'ARDS' named entity 'INFLAMMATORY MEDIATORS' named entity 'C-reactive protein' named entity 'reasonable' named entity 'constituted' named entity 'inflammatory mediators' named entity 'exchanges' named entity 'Case' named entity 'chest imaging' named entity 'SARS-COV-2' named entity 'IL-6' named entity 'inflammatory cytokines' named entity 'C-reactive protein' named entity 'IL-6' named entity 'interstitial pneumonia' named entity 'Blood levels' named entity 'Tocilizumab' named entity 'normal range' named entity 'extracorporeal membrane oxygenation' named entity 'C-reactive protein' named entity 'tocilizumab' named entity 'interstitial pneumonia' named entity 'IL-6' named entity 'blood oxygenation' named entity 'rheumatoid arthritis' named entity 'ICU' named entity 'interstitial pneumonia' named entity 'pneumonia' named entity 'procalcitonin' named entity 'endothelial' named entity 'acute-phase reactant' named entity 'systemic inflammation' named entity 'tocilizumab' named entity 'molecular weight' named entity 'inflammatory' named entity 'chimeric antibody' named entity 'inflammation' named entity 'bronchoalveolar lavage' named entity 'free of symptoms' named entity 'receptor' named entity 'coronavirus disease' named entity 'CytoSorbents' named entity 'immune response' named entity 'septic shock' named entity 'anticoagulation' named entity 'ARDS' named entity 'tocilizumab' named entity 'CRP' named entity 'antiviral agents' named entity 'hepatomegaly' named entity 'ARDS' named entity 'clinical investigations' named entity 'interleukin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software